344 related articles for article (PubMed ID: 24624361)
21. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
22. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
[TBL] [Abstract][Full Text] [Related]
23. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
24. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
25. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
26. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
Murthy P; Muggia F
Ecancermedicalscience; 2019; 13():904. PubMed ID: 30915162
[TBL] [Abstract][Full Text] [Related]
27. [Medical treatment options in BRCA-associated cancers].
Kahán Z
Magy Onkol; 2020 Mar; 64(1):13-24. PubMed ID: 32181758
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan RD; Clamp AR; Evans DGR; Edmondson RJ; Jayson GC
Cancer Chemother Pharmacol; 2018 Apr; 81(4):647-658. PubMed ID: 29464354
[TBL] [Abstract][Full Text] [Related]
29. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
30. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
31. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
33. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
34. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
35. Update on PARP1 inhibitors in ovarian cancer.
Sessa C
Ann Oncol; 2011 Dec; 22 Suppl 8():viii72-viii76. PubMed ID: 22180407
[TBL] [Abstract][Full Text] [Related]
36. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
37. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
38. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
39. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
40. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
